Home Tags AbbVie
Dispensed: Pharma’s next big megamerger, a string of healthcare IPOs, and why the CEO of Clover Health regrets setting up shop in Silicon Valley...
Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here’s how the Botox-ma...
Here's how Allergan went from its start as a sleepy but beloved company out of Southern California in the 1950s to an acquisition target for AbbVie.
AbbVie expects the acquisition to generate at least $2 billion in pre-tax synergies and cost reductions within three years.
The biopharmaceuticals giant and drugmaker want to create a leader across immunology, neuroscience, eye care, and other medical fields.
AbbVie just stopped enrolling patients in a late-stage trial of a high-profile lung cancer drug after patients had shorter survival results on the drug.
A company that’s taking a new approach to tackling Alzheimer’s is moving into human trials after raising $133 million
Biotech startup Alector is getting ready to put its first batch of neurodegenerative drugs into humans after raising an additional $133 million. Alector is developing treatments that harness the body's immune system to tackle conditions like Alzheimer's, and other forms of dementia.
A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just...
The FDA just approved elagolix, a new treatment for women living with endometriosis. Endometriosis, a condition that affects millions of women, occurs when tissue from the uterus grows outside of it, leading to cysts, heavy bleeding, and scarring.
‘Nobody’s talking about’ 2 medical conditions that affect 8 million women in America — but that could be about to change
The drugs in development are to treat two major women's health conditions: endometriosis and uterine fibroids.
The Reputation Institute took a look at what the general public thought of 17 major pharmaceutical companies. Here's who came out on top.